Patents by Inventor Jan Hoflack

Jan Hoflack has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Macrocyclic RIP2 kinase inhibitors
    Patent number: 10676486
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: June 9, 2020
    Assignee: ONCODESIGN S.A.
    Inventors: Jan Hoflack, Petra Blom, Pascal Benderitter
  • Macrocyclic LRRK2 kinase inhibitors
    Patent number: 10377772
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 17, 2015
    Date of Patent: August 13, 2019
    Assignee: Oncodesign S.A.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • MACROCYCLIC RIP2 KINASE INHIBITORS
    Publication number: 20190127390
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of RIP2 and/or mutants thereof, for use in the diagnosis, prevention and/or treatment of RIP2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent.
    Type: Application
    Filed: September 17, 2015
    Publication date: May 2, 2019
    Applicant: ONCODESIGN S.A.
    Inventors: Jan Hoflack, Petra Blom, Pascal Benderitter
  • MACROCYCLIC LRRK2 KINASE INHIBITORS
    Publication number: 20170240565
    Abstract: The present invention relates to novel macrocyclic compounds of formula (I) and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: September 17, 2015
    Publication date: August 24, 2017
    Applicants: Oncodesign S.A., Ipsen Pharma S.A.S.
    Inventors: Jan Hoflack, Petra Blom, Olivier Lavergne, Sylvie Gomez
  • Macrocyclic LRRK2 kinase inhibitors
    Patent number: 9370520
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: June 23, 2015
    Date of Patent: June 21, 2016
    Assignee: IPSEN PHARMA S.A.S.
    Inventors: Jan Hoflack, Petra Blom
  • Macrocyclic LRRK2 Kinase Inhibitors
    Publication number: 20160031905
    Abstract: The present invention relates to macrocyclic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 kinase, for use in the diagnosis, prevention and/or treatment of LRRK2-kinase associated diseases. Moreover, the present invention provides methods of using said compounds, for instance as a medicine or diagnostic agent. Finally, the present invention also relates to new macrocyclic compounds.
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Jan HOFLACK, Petra BLOM, Olivier LAVERGNE
  • MACROCYCLIC LRRK2 KINASE INHIBITORS
    Publication number: 20150290198
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: June 23, 2015
    Publication date: October 15, 2015
    Inventors: Jan HOFLACK, Petra BLOM
  • Macrocyclic LRRK2 kinase inhibitors
    Patent number: 9096609
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Grant
    Filed: September 28, 2012
    Date of Patent: August 4, 2015
    Assignees: Ipsen Pharma S.A.S., Oncodesign S.A.
    Inventors: Jan Hoflack, Petra Blom
  • MACROCYCLIC LRRK2 KINASE INHIBITORS
    Publication number: 20140206683
    Abstract: The present invention relates to novel macrocylic compounds and compositions containing said compounds acting as kinase inhibitors, in particular as inhibitors of LRRK2 (Leucine-Rich Repeat Kinase 2). Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine or diagnostic agent, in particular for the treatment and/or diagnosis of diseases characterized by LRRK2 kinase activity such as neurological disorders including Parkinson's disease and Alzheimer's disease.
    Type: Application
    Filed: September 28, 2012
    Publication date: July 24, 2014
    Inventors: Jan Hoflack, Petra Blom